Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1998 Jul;51(7):502–505. doi: 10.1136/jcp.51.7.502

The identification of salicylates as normal constituents of serum: a link between diet and health?

J R Paterson 1, C Blacklock 1, G Campbell 1, D Wiles 1, J R Lawrence 1
PMCID: PMC500801  PMID: 9797725

Abstract

AIM: To examine sera for the presence of salicylic acid and 2,3- and 2,5-dihydroxybenzoic acids (2,3- and 2,5-DHBA), in individuals not taking salicylate drugs. METHODS: Extracts of acidified serum samples were analysed by high performance liquid chromatography with electro-chemical detection. The chromatographic conditions were altered, and the retention times of the unknown compounds compared against authentic salicylic acid, 2,3-DHBA, and 2,5-DHBA. Serum samples (some spiked with salicylic acid) were incubated with salicylate hydroxylase and analyses undertaken. An extract of acidified serum was derivatised using N-methyl-N-trimethylsilyltrifluoroacetamide and the salicylic acid derivative identified by gas chromatography-mass spectrometry. RESULTS: Salicylic acid, 2,3-DHBA, and 2,5-DHBA were identified as being normal constituents of serum. CONCLUSIONS: Salicylic acid, 2,3-DHBA, and 2,5-DHBA possess anti-inflammatory properties. The finding that these compounds are present as normal constituents of serum, possibly arising from diet, raises important questions as to their role in the promotion of health.

Full text

PDF
502

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blackwell G. J., Flower R. J., Vane J. R. Some characteristics of the prostaglandin synthesizing system in rabbit kidney microsomes. Biochim Biophys Acta. 1975 Jul 22;398(1):178–190. doi: 10.1016/0005-2760(75)90181-2. [DOI] [PubMed] [Google Scholar]
  2. Coudray C., Mangournet C., Bouhadjeb S., Faure H., Favier A. Rapid high-performance liquid chromatographic assay for salicylic acid in plasma without solvent extraction. J Chromatogr Sci. 1996 Apr;34(4):166–173. doi: 10.1093/chromsci/34.4.166. [DOI] [PubMed] [Google Scholar]
  3. Davison C. Salicylate metabolism in man. Ann N Y Acad Sci. 1971 Jul 6;179:249–268. doi: 10.1111/j.1749-6632.1971.tb46905.x. [DOI] [PubMed] [Google Scholar]
  4. Elder D. J., Hague A., Hicks D. J., Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines. Cancer Res. 1996 May 15;56(10):2273–2276. [PubMed] [Google Scholar]
  5. Flower R. J. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 1974 Mar;26(1):33–67. [PubMed] [Google Scholar]
  6. Grootveld M., Halliwell B. 2,3-Dihydroxybenzoic acid is a product of human aspirin metabolism. Biochem Pharmacol. 1988 Jan 15;37(2):271–280. doi: 10.1016/0006-2952(88)90729-0. [DOI] [PubMed] [Google Scholar]
  7. Haynes D. R., Wright P. F., Gadd S. J., Whitehouse M. W., Vernon-Roberts B. Is aspirin a prodrug for antioxidant and cytokine-modulating oxymetabolites? Agents Actions. 1993 May;39(1-2):49–58. doi: 10.1007/BF01975714. [DOI] [PubMed] [Google Scholar]
  8. Higgs G. A., Salmon J. A., Henderson B., Vane J. R. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci U S A. 1987 Mar;84(5):1417–1420. doi: 10.1073/pnas.84.5.1417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Janssen P. L., Hollman P. C., Reichman E., Venema D. P., van Staveren W. A., Katan M. B. Urinary salicylate excretion in subjects eating a variety of diets shows that amounts of bioavailable salicylates in foods are low. Am J Clin Nutr. 1996 Nov;64(5):743–747. doi: 10.1093/ajcn/64.5.743. [DOI] [PubMed] [Google Scholar]
  10. Kargman S. L., O'Neill G. P., Vickers P. J., Evans J. F., Mancini J. A., Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 1995 Jun 15;55(12):2556–2559. [PubMed] [Google Scholar]
  11. Marcus A. J. Aspirin as prophylaxis against colorectal cancer. N Engl J Med. 1995 Sep 7;333(10):656–658. doi: 10.1056/NEJM199509073331011. [DOI] [PubMed] [Google Scholar]
  12. McGuire W. P., Hoskins W. J., Brady M. F., Kucera P. R., Partridge E. E., Look K. Y., Clarke-Pearson D. L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 4;334(1):1–6. doi: 10.1056/NEJM199601043340101. [DOI] [PubMed] [Google Scholar]
  13. Muller C. J., Fugelsang K. C. Take two glasses of wine and see me in the morning. Lancet. 1994 Jun 4;343(8910):1428–1429. doi: 10.1016/s0140-6736(94)92550-x. [DOI] [PubMed] [Google Scholar]
  14. Paganini-Hill A. Aspirin and the prevention of colorectal cancer: a review of the evidence. Semin Surg Oncol. 1994 May-Jun;10(3):158–164. doi: 10.1002/ssu.2980100303. [DOI] [PubMed] [Google Scholar]
  15. Ridker P. M., Cushman M., Stampfer M. J., Tracy R. P., Hennekens C. H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997 Apr 3;336(14):973–979. doi: 10.1056/NEJM199704033361401. [DOI] [PubMed] [Google Scholar]
  16. Ruffin M. T., 4th, Krishnan K., Rock C. L., Normolle D., Vaerten M. A., Peters-Golden M., Crowell J., Kelloff G., Boland C. R., Brenner D. E. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst. 1997 Aug 6;89(15):1152–1160. doi: 10.1093/jnci/89.15.1152. [DOI] [PubMed] [Google Scholar]
  17. Vree T. B., van Ewijk-Beneken Kolmer E. W., Verwey-van Wissen C. P., Hekster Y. A. Direct gradient reversed-phase high-performance liquid chromatographic determination of salicylic acid, with the corresponding glycine and glucuronide conjugates in human plasma and urine. J Chromatogr. 1994 Feb 11;652(2):161–170. doi: 10.1016/0378-4347(93)e0381-y. [DOI] [PubMed] [Google Scholar]
  18. Williams C. S., DuBois R. N. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol. 1996 Mar;270(3 Pt 1):G393–G400. doi: 10.1152/ajpgi.1996.270.3.G393. [DOI] [PubMed] [Google Scholar]
  19. Wu K. K., Sanduja R., Tsai A. L., Ferhanoglu B., Loose-Mitchell D. S. Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2384–2387. doi: 10.1073/pnas.88.6.2384. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES